At the news
? BULLISHIMPACT 7/10 6-K filed Apr 20, 2026 at 07:03 ET
AstraZeneca announced positive high-level results from the Phase III MIRANDA trial, showing that tozorakimab significantly reduced moderate-to-severe COPD exacerbations. This marks the third successful pivotal trial for the drug, reinforcing its potential as a first-in-class IL-33-targeting biologic.
- Tozorakimab met the primary endpoint in the Phase III MIRANDA trial, demonstrating a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations.
- This is the third positive pivotal Phase III trial for tozorakimab, following prior successes in the OBERON and TITANIA trials.
- The MIRANDA trial evaluated a biweekly dosing regimen, expanding on previous monthly dosing data.
- Tozorakimab was generally well tolerated with a safety profile consistent with prior trials.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access